Role of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia

This was a double-blinded placebo-controlled clinical trial, which including 98 patients clinically diagnosed as various degrees of benign prostatic hyperplasia and confirmed by pelvic ultrasonography along with uroflowmetry investigations. Himplasia was administered as 1 tablet, twice daily for 6 months. All the patients were clinically examined every month for 6 months and we repeat ultrasonography and uroflowmetry after 6 months treatment with Himplasia. There was excellent compliance with Himplasia. All 98 patients completed the treatment and patient reported any side effects. Himplasia significantly relieved the symptoms of BPH along with reduction in prostate size revealed by pelvic ultrasonography. Himplasia acts by dual mode of action which is by inhibition of 5-alpha reductase enzyme inhibition with alpha receptor blocking action. By this Himplasia controls the conversion of testosterone to dihydrotestosterone along with relaxation of prostatic smooth muscles. Himplasia may be considered as a therapy for patients with benign prostatic hyperplasia.